Guttman-Yassky E, Thaçi D, Pangan AL, et al. - Among patients with moderate-to-severe atopic dermatitis, researchers tested the effectiveness and safety of multiple doses of the selective Janus kinase 1 inhibitor upadacitinib. In the 16-week, double-blind, placebo-controlled, parallel-group, dose-ranging portion of this 88-week study in 8 countries, adults with moderate-to-severe disease and insufficient topical treatment control were randomized 1:1:1:1, utiliZing an interactive response system and geographically stratified, to once-daily upadacitinib oral monotherapy 7.5, 15, or 30 mg or placebo. One hundred sixty-seven patients enrolled from November 21, 2016, to April 20, 2017. For the effectiveness of upadacitinib, a dose-response relationship was observed. The highest clinical benefit was shown by the 30 mg once daily dose. There was no observed dose-limiting toxicity.